Stockscreener 앱 받기
1.02%
시간 외 거래:
전일 마감가:
$2.93
열려 있는:
$2.94
하루 거래량:
1.99M
Relative Volume:
0.51
시가총액:
$563.98M
수익:
$41,000
순이익/손실:
$-88.09M
주가수익비율:
-2.856
EPS:
-1.0154
순현금흐름:
$-67.55M
1주 성능:
+1.75%
1개월 성능:
-16.43%
6개월 성능:
-39.71%
1년 성능:
-49.74%
1일 변동 폭
$2.88
$3.00
1주일 범위
$2.72
$3.00
52주 변동 폭
$2.56
$7.73
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
2.90 | 569.81M | 41,000 | -88.09M | -67.55M | -1.0154 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 업그레이드 | Goldman | Sell → Neutral |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Here's why you should add Altimmune stock to your portfolio now - MSN
Altimmune's Q1 loss narrower than expected, revenues nil - MSN
Here's Why You Should Add Altimmune Stock to Your Portfolio Now - Yahoo Finance
Altimmune Q3 2025 Earnings Preview - MSN
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
H.C. Wainwright cuts Altimmune stock price target on dilution - Investing.com India
H.C. Wainwright cuts Altimmune stock price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Several Insiders Invested In Altimmune Flagging Positive News - simplywall.st
ALT Maintained by HC Wainwright & Co. -- Price Target Lowered to $20 - GuruFocus
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Altimmune Price Target Cut to $20.00/Share From $25.00 by HC Wainwright & Co. - Moomoo
Altimmune Inc Price USD, ALT Price Live Charts, Market Cap & News - Bitget
ALT: Altimmune Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Altimmune Inc (ALT) Stock Price, Quote, News & History - Benzinga
Tang Capital (ALT) reports 666,022 shares, 0.3% stake in Altimmune (ALT) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ALT Maintained by Citizens -- Price Target Lowered to $11.00 - GuruFocus
Altimmune Is Maintained at Market Outperform by Citizens - Moomoo
Truist Financial Maintains Altimmune(ALT.US) With Buy Rating - Moomoo
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil - The Globe and Mail
Altimmune heads to Barcelona for EASL26 to engage global liver disease specialists - Traders Union
A Quick Look at Today's Ratings for Altimmune(ALT.US), With a Forecast Between $11 to $20 - Moomoo
Citizens cuts Altimmune stock price target on increased share count By Investing.com - Investing.com Nigeria
Altimmune, Inc. (NASDAQ:ALT) Q1 2026 Earnings Call Transcript - Insider Monkey
Altimmune shares rise over 3% on beating first quarter loss estimates - Investing.com
Citizens cuts Altimmune stock price target on increased share count - Investing.com
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):